Re-irradiation results of fractionated stereotactic radiotherapy (FSRT) with cyberknife for locally-advanced nasopharengeal carcinoma (NPC)

The median re-irradiation FSRTdose was 30Gy in 5 fractions.Results: Median follow-up was44 (22-179)months, the overall survival(OS) rate, local failure-free survival (LFFS ) and disease progression-free survival(DPFS) rate at 3 years were 89%,73% and 53%, respectively.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Aim: Recurrent nasopharyngeal carcinoma (NPC) after previous radiation therapy is a major problem.

📊

Key Findings & Data:This study was conducted to determine the survival benefits and potential benefits of the effects of severe late toxicities by re-irradiation with fractionated stereotactic radiotherapy (FSRT).Material and Methods: 2009-2018, treatment outcomes were evaluated retrospectively in 26 patients with local recurrent NPC were cured applying FSRT with Cyberknife.

💡

Conclusion & Impact:The median re-irradiation FSRTdose was 30Gy in 5 fractions.Results: Median follow-up was44 (22-179)months, the overall survival(OS) rate, local failure-free survival (LFFS ) and disease progression-free survival(DPFS) rate at 3 years were 89%,73% and 53%, respectively.

🔬Design:Research Article

📍Scope:2009-2018 Verileri

⚙️Variables:Domain Parameters

Abstract

Aim: Recurrent nasopharyngeal carcinoma (NPC) after previous radiation therapy is a major problem. This study was conducted to determine the survival benefits and potential benefits of the effects of severe late toxicities by re-irradiation with fractionated stereotactic radiotherapy (FSRT).Material and Methods: 2009-2018, treatment outcomes were evaluated retrospectively in 26 patients with local recurrent NPC were cured applying FSRT with Cyberknife. Five patients had metastatic disease and one had second recurrence was excluded from the research, remaining 20 patients were analyzed. Median agewas 52 years (range,28-80 years), re-treatment T stagewas; 6 (30%) T2, 5 (25%) T3, 9 (45%) T4.Median time from initial RT to recurrence was 22 months (range,8-159 mo.). The median re-irradiation FSRTdose was 30Gy in 5 fractions.Results: Median follow-up was44 (22-179)months, the overall survival(OS) rate, local failure-free survival (LFFS ) and disease progression-free survival(DPFS) rate at 3 years were 89%,73% and 53%, respectively. All patients were evaluated for response after treatment; 9 (45%) had complete, 3 (15%) partial, 6 (%30) had no response.Univariate analysis demonstrated that; higher cumulativetotal radiotherapy dose, gross tumor volume and recurrent time interval were prognostic factors for LFFS. Recurrent time interval was also independent factor for DPFS and OS. The incidence of temporal lobe necrosis and trismus were 10% and 20%,respectively. One patient had grade 5 toxicity to treatment related bleeding.Conclusion: Tumor dose coverage is critical for treating recurrent NPC and treatment linked death rate was vascular in nature. Fractionated stereotactic radiotherapy is promising treatment modality for recurrent NPC.

🔖

Cite This Article

YAPRAK, G., IŞIK, N., DOGAN, O. Y., DEMİRCİOGLU, F., ALGUL, E., BICAKCI, B. C., ÖZYURT, H. (2022). Re-irradiation results of fractionated stereotactic radiotherapy (FSRT) with cyberknife for locally-advanced nasopharengeal carcinoma (NPC). Annals of Medical Research, Cilt: 27 - Sayı: 9, 2370–2376. https://ajindex.com/articles/446577

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Lee N, Xia P, Quivey JM,, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol BiolPhys 2002;53:12-22
Peng G, Wang T, Yang KY, et al.A prospective, randomized study comparing out comes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012;104:286-93
Lee N, Harris J, Garden AS,et al. Intensity-modulated radiation therapy with or with out chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.J Clin Oncol 2009;27:3684-90
Han F, Zhao C, Huang SM, et al. Long-term out comes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensitymodulated radiotherapy. Clin Oncol (R CollRadiol) 2012;24:569-76
Hua YJ, Han F, Lu LX, et al. Long-term treatment out come of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer 2012;48: 3422-8
Qiu S, Lin S, Tham IW,et al. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2012;83:676-83
Yamazaki H,Demizu Y, Okimoto T, et al. Comparison of re-irradiation outcomes for charged particle radiotherapy and robotic stereotactic radiotherapy using cyberknife for recurrent head and neck cancers: a multi-institutional matched-cohort analysis. Anticancer Res 2016;36:5507-14
Takagi M, Demizu Y, Hashimoto N, et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck. Radiother Oncol 2014;113: 364-70
Morimoto K, Demizu Y, Hashimoto N, et al. Particle radiotherapy using protons or carbon ions for unresectable locally advanced head and neck cancers with skullbase invasion. Jpn J Clin Oncol 2014;44: 428-34
Demizu Y, Fujii O, Terashima K, et al. Particle therapy for mucosal melanoma of the head and neck. A single institution retrospective comparison of proton and carbon ion therapy. Strahlenther Onkol 2014;190: 186-91
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81
Chua DT, Sham JS, Kwong DL, et al. Locally recurrent nasopharyngeal carcinoma: treatment results for patie